| Lori-ann Bissell, | |
|
4000 Wellness Dr, Midland, MI 48670-2000 | |
| (989) 839-3000 | |
| Not Available |
| Full Name | Lori-ann Bissell |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 4000 Wellness Dr, Midland, Michigan |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033681259 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Lori-ann Bissell, 856 W Blue Grass Rd, Mount Pleasant, MI 48858-9566 Ph: () - | Lori-ann Bissell, 4000 Wellness Dr, Midland, MI 48670-2000 Ph: (989) 839-3000 |
News Archive
Mayo Clinic researchers say that "teachable software" designed to mimic the human brain may help them diagnose cardiac infections without an invasive exam. Those findings are being presented today at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco.
Patients suffering from chronic obstructive pulmonary disease (COPD) typically suffer from depression more frequently than those without COPD, resulting in higher levels of disability and illness and increasing the overall healthcare burden for the COPD population.
Women respond much better than men to the treatment of chronic follicular lymphoma with a monoclonal antibody that targets CD20 (rituximab). These are the findings of a multi-centre, Austria-wide study by the Arbeitsgemeinschaft medikamentöse Tumortherapie (AGMT) carried out under the supervision of the University Department of Internal Medicine I and study leader Ulrich Jäger, which has now been published in the highly respected journal "Haematologica".
Liggins Institute Director and trial Director Professor Peter Gluckman said the CoolCap trial results were the culmination of over 20 years work and provided the first evidence in humans that brain damage at birth could be treated. The findings offered hope for a new approach to a major set of clinical conditions, he said.
Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced that the company has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for Silenor® (doxepin) for the treatment of insomnia.
› Verified 8 days ago
Mrs. Stephanie Damore, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2670 E Miller Rd, Midland, MI 48640 Phone: 989-751-4807 | |
Kaitlan Smith, CF Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 4401 Campus Ridge Dr Ste 1100, Midland, MI 48640 Phone: 989-128-5200 | |
Brooke Smith, M.S., CCC-SLP Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 1525 Ridgewood Dr, Midland, MI 48642 Phone: 989-835-6333 | |
Sherry Swier, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1525 Ridgewood Dr, Midland, MI 48642 Phone: 989-835-6333 Fax: 989-835-4920 | |
Jenna Ann Randolph, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 4000 Wellness Dr, Midland, MI 48670 Phone: 989-824-1148 | |
Nicole Braun, M.A., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1525 Ridgewood Dr, Midland, MI 48642 Phone: 989-835-6333 |